Ebola vaccine response when given before or after treatment
Part of Infections clinical trials.
This study looks at whether giving an Ebola treatment (Inmazeb) before the Ebola vaccine (Ervebo) changes the vaccine's effect on healthy people. It helps understand the best timing for these treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a healthy adult.
- You must be available for the entire study follow-up period.
- You must agree not to join any other clinical trial during the study.
- You cannot have had Ebola before.
- You cannot have received any Ebola vaccine or Ebola antibody treatment before.
- You cannot be HIV positive, pregnant, breastfeeding, or taking immune-suppressing medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine to prevent Ebola after you have been exposed. If you had close contact with someone who has Ebola in the last 5 days, this study could help you stay healthy.
This study tests if a booster dose of one of two Ebola vaccines (Ervebo® or Zabdeno®) is safe and works well in people who already got an Ebola vaccine more than 4 months ago. It's especially for people living in the Democratic Republic of Congo (DRC) who may have been vaccinated before and might need a stronger, longer-lasting immune response.
This trial provides an experimental antibody treatment called ansuvimab to people who have Ebola or have been recently exposed to it. The goal is to help their bodies fight the virus and prevent illness.
This trial provides an experimental antibody treatment called REGN-EB3 to people infected with Ebola virus. It aims to treat the infection and potentially improve recovery, and is available through special access in areas with Ebola outbreaks.
This study tests a new Ebola vaccine to see if it is safe and how well it works. Healthy volunteers receive the vaccine and are monitored for side effects and immune response.
This study tests a new vaccine, V4020, that may help protect against Venezuelan equine encephalitis (VEE), a rare but serious virus spread by mosquitoes. It is the first step in humans to see if it is safe and how the body responds.
Hear when a new Ebola Virus Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.